.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,229,630

« Back to Dashboard
Patent 7,229,630 protects ORAVERSE and is included in one NDA.

This patent has fifteen patent family members in twelve countries.

Summary for Patent: 7,229,630

Title:Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
Abstract:The present invention provides compositions and stable liquid formulations comprising alpha adrenergic receptor antagonists and use thereof for increasing blood flow. In one embodiment, the stable liquid formulations of this invention are useful for reversing the effects of an anesthetic agent, preferably a long-lasting local anesthetic agent administered in conjunction with an alpha adrenergic receptor agonist.
Inventor(s): Chen; Andrew X. (San Diego, CA), Knowles; Julius (Del Mar, CA), Weber; Eckard (San Diego, CA)
Assignee: Novalar Pharmaceuticals, Inc. (DE)
Application Number:10/465,810
Patent Claim Types:
see list of patent claims
Formulation; Compound; Use; Dosage form; Composition; Device;
Patent Metrics:
Source: PatentQuant.com
Field: Pharmaceuticals
Back Citations: 14th percentile
Forward Citations: 0th percentile

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Septodont Holding
ORAVERSE
phentolamine mesylate
INJECTABLE;INJECTION022159-001May 9, 2008RXYes7,229,630► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,229,630

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,575,757Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof► subscribe
7,569,230Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,229,630

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Norway20050300► subscribe
MexicoPA04012507► subscribe
Japan2010280702► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc